Get the Stockscreener App
65.84
2.68%
-1.885
Bridgebio Pharma Inc stock is traded at $65.84, with a volume of 1.25M.
It is down -2.68% in the last 24 hours and down -11.55% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$67.73
Open:
$68.06
24h Volume:
1.25M
Relative Volume:
0.51
Market Cap:
$12.90B
Revenue:
$502.08M
Net Income/Loss:
$-732.94M
P/E Ratio:
-17.40
EPS:
-3.7842
Net Cash Flow:
$-455.50M
1W Performance:
-3.38%
1M Performance:
-11.55%
6M Performance:
-8.09%
1Y Performance:
+99.14%
1-Day Range:
$65.55
$68.12
1-Week Range:
$65.55
$71.74
52-Week Range:
$31.77
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
65.85 | 13.27B | 502.08M | -732.94M | -455.50M | -3.7842 |
VRTX
Vertex Pharmaceuticals Inc
|
441.12 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
627.54 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
822.85 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.44 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.97 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | RBC Capital Mkts | Outperform |
| Mar-10-26 | Initiated | William Blair | Outperform |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-06-26 | Initiated | Morgan Stanley | Overweight |
| Dec-11-25 | Initiated | Bernstein | Outperform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jul-09-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
BridgeBio Pharma (BBIO) Shares Rise on FDA Priority Review for BBP-418 - GuruFocus
BridgeBio (BBIO) Secures FDA Filing Acceptance for BBP-418 - GuruFocus
BridgeBio gains FDA review for muscle disorder drug (BBIO) - Seeking Alpha
BridgeBio Pharma Announces FDA Acceptance of BBP-418 NDA for Limb-Girdle Muscular Dystrophy Type 2I/R9 with Priority Review Status - Quiver Quantitative
BridgeBio’s LGMD2I/R9 drug receives FDA priority review - Investing.com
FDA priority review for first potential LGMD2I/R9 treatment - Stock Titan
Biotech BridgeBio hands new recruits 31,428 stock units - Stock Titan
Raymond James downgrades BridgeBio Pharma (BBIO) - MSN
BridgeBio Pharma Shares Fall After Raymond James Downgrade - Moomoo
Bridgebio Pharma Insider Sold Shares Worth $1,812,522, According to a Recent SEC Filing - marketscreener.com
BridgeBio (BBIO) CEO Neil Kumar sells 26,103 shares in Rule 10b5-1 trades - Stock Titan
BridgeBio Pharma (BBIO) Downgraded by Raymond James Amid Competi - GuruFocus
Breakeven On The Horizon For BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Moomoo
BridgeBio Pharma (BBIO) Downgraded by Raymond James Amid Competitive Pressures - GuruFocus
BridgeBio stock downgraded at Raymond James (PFE:NYSE) - Seeking Alpha
Raymond James downgrades BridgeBio Pharma stock rating on payer risks By Investing.com - Investing.com Canada
BridgeBio Pharma, Inc. (BBIO) Growth Potential: Analyst Ratings Signal 47% Upside - DirectorsTalk Interviews
Technical Reactions to BBIO Trends in Macro Strategies - Stock Traders Daily
BridgeBio gains amid report of settlement in Pfizer Vyndamax patent dispute - MSN
BBIO (NASDAQ: BBIO) trust sells repeated 20,000-share blocks under 10b5-1 - Stock Titan
BBIO Stock Price Prediction 2025-2026 | BridgeBio Pharma Inc Forecast - 24/7 Wall St.
BridgeBio’s SWOT analysis: rare disease stock eyes profitability By Investing.com - Investing.com Canada
BridgeBio’s SWOT analysis: rare disease stock eyes profitability - Investing.com
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Cullinan Management (CGEM) - The Globe and Mail
BBIO Initiates Coverage by Citigroup -- Rating Set to Neutral - GuruFocus
J.P. Morgan Initiates BridgeBio Pharma(BBIO.US) With Hold Rating, Announces Target Price $82 - Moomoo
Bridgebio Pharma Insider Sold Shares Worth $671,456, According to a Recent SEC Filing - Moomoo
[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity - Stock Titan
BridgeBio Pharma (BBIO) CEO reports RSU vesting and tax withholding share disposition - Stock Titan
BridgeBio (BBIO) CAO has 4,714 shares withheld at $66.13 for RSU taxes - Stock Titan
BridgeBio Pharma (BBIO) director exercises options and sells 10,000 shares - Stock Titan
Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn’t a Slam Dunk - Yahoo Finance
BridgeBio falls despite new Attruby data - MSN
Citigroup initiates coverage of BridgeBio Pharma (BBIO) with neutral recommendation - MSN
[144] BridgeBio Pharma, Inc. SEC Filing - Stock Titan
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Exploring a 55% Potential Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
VIRGINIA RETIREMENT SYSTEMS ET Al Increases Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Janus Henderson (BBIO) discloses 13,179,013 shares, 6.8% ownership - Stock Titan
How Encaleret’s NDA and New Acoramidis Milestones Could Reframe BridgeBio Pharma (BBIO) Investors’ Outlook - Yahoo Finance
BridgeBio (BBIO) Q1 2026 Earnings Transcript - AOL.com
BridgeBio Pharma stock (US10806X1028): Pipeline progress in rare diseases - AD HOC NEWS
Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Palisade Bio (PALI) - The Globe and Mail
BridgeBio outlines $500M share repurchase as it targets P&L breakeven in 2027 - MSN
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $101 - Moomoo
BridgeBio Files FDA NDA for Encaleret in ADH1 - TipRanks
BridgeBio (NASDAQ: BBIO) files NDA as encaleret hits Phase 3 goals in ADH1 - Stock Titan
Evercore ISI Retains an “Outperform Rating” on BridgeBio Pharma, Inc. (BBIO) - Insider Monkey
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches - Barchart.com
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX) and BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026Slideshow - Seeking Alpha
BridgeBio Oncology (NASDAQ: BBOT) ramps R&D and deepens Q1 2026 loss - Stock Titan
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
1.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):